These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25669148)

  • 1. Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.
    Fukuyama Y; Yuki Y; Katakai Y; Harada N; Takahashi H; Takeda S; Mejima M; Joo S; Kurokawa S; Sawada S; Shibata H; Park EJ; Fujihashi K; Briles DE; Yasutomi Y; Tsukada H; Akiyoshi K; Kiyono H
    Mucosal Immunol; 2015 Sep; 8(5):1144-53. PubMed ID: 25669148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
    Kong IG; Sato A; Yuki Y; Nochi T; Takahashi H; Sawada S; Mejima M; Kurokawa S; Okada K; Sato S; Briles DE; Kunisawa J; Inoue Y; Yamamoto M; Akiyoshi K; Kiyono H
    Infect Immun; 2013 May; 81(5):1625-34. PubMed ID: 23460513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.
    Nakahashi-Ouchida R; Uchida Y; Yuki Y; Katakai Y; Yamanoue T; Ogawa H; Munesue Y; Nakano N; Hanari K; Miyazaki T; Saito Y; Umemoto S; Sawada SI; Mukerji R; Briles DE; Yasutomi Y; Akiyoshi K; Kiyono H
    Vaccine; 2021 Jun; 39(25):3353-3364. PubMed ID: 34016473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery System.
    Yuki Y; Uchida Y; Sawada SI; Nakahashi-Ouchida R; Sugiura K; Mori H; Yamanoue T; Machita T; Honma A; Kurokawa S; Mukerji R; Briles DE; Akiyoshi K; Kiyono H
    Mol Pharm; 2021 Apr; 18(4):1582-1592. PubMed ID: 33621107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.
    Kataoka K; Fujihashi K; Oma K; Fukuyama Y; Hollingshead SK; Sekine S; Kawabata S; Ito HO; Briles DE; Oishi K
    Infect Immun; 2011 Jul; 79(7):2819-28. PubMed ID: 21536790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.
    Yuki Y; Harada N; Sawada SI; Uchida Y; Nakahashi-Ouchida R; Mori H; Yamanoue T; Machita T; Kanazawa M; Fukumoto D; Ohba H; Miyazaki T; Akiyoshi K; Fujihashi K; Kiyono H
    Vaccine; 2023 Jul; 41(34):4941-4949. PubMed ID: 37385890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.
    Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH
    Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.
    Nochi T; Yuki Y; Takahashi H; Sawada S; Mejima M; Kohda T; Harada N; Kong IG; Sato A; Kataoka N; Tokuhara D; Kurokawa S; Takahashi Y; Tsukada H; Kozaki S; Akiyoshi K; Kiyono H
    Nat Mater; 2010 Jul; 9(7):572-8. PubMed ID: 20562880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
    Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
    Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
    Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
    Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice.
    Fukuyama Y; King JD; Kataoka K; Kobayashi R; Gilbert RS; Hollingshead SK; Briles DE; Fujihashi K
    J Immunol; 2011 Feb; 186(4):2454-61. PubMed ID: 21242514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice.
    Ezoe H; Akeda Y; Piao Z; Aoshi T; Koyama S; Tanimoto T; Ishii KJ; Oishi K
    Vaccine; 2011 Feb; 29(9):1754-61. PubMed ID: 21219977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).
    Genschmer KR; Accavitti-Loper MA; Briles DE
    Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents.
    Azegami T; Yuki Y; Hayashi K; Hishikawa A; Sawada SI; Ishige K; Akiyoshi K; Kiyono H; Itoh H
    J Hypertens; 2018 Feb; 36(2):387-394. PubMed ID: 28832363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
    Salcedo-Rivillas C; Debrie AS; Miyaji EN; Ferreira JM; Raw I; Locht C; Ho PL; Mielcarek N; Oliveira ML
    Clin Vaccine Immunol; 2014 Jul; 21(7):972-81. PubMed ID: 24807055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.